Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : Pfe save search
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
Published: 2023-12-08 (Crawled : 16:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2023-06-01 (Crawled : 17:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 0.26%
H: 0.24%
C: -0.26%
hope treatment infections
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: -0.39%
H: 0.07%
C: -0.46%
talzenna positive study
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 3.11%
H: 0.88%
C: 0.02%
candidate global vaccine respiratory virus trial positive
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published: 2022-08-25 (Crawled : 11:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: 0.8%
candidate vaccine respiratory virus trial positive
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 01:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results topline license phase 3 ulcerative colitis
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential
Published: 2022-03-29 (Crawled : 11:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 1.35%
H: 0.15%
C: -2.33%
trial potential positive results phase 3 topline ulcerative colitis
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients
Published: 2022-03-23 (Crawled : 12:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
trial positive results phase 3 topline ulcerative colitis
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
Published: 2022-03-01 (Crawled : 13:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
trial disease potential vaccine phase 3
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
Published: 2022-01-12 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.0354 320
|
Communications
|
| O: 0.0%
H: 0.0%
C: 0.0%
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: -0.77%
H: 1.46%
C: 0.55%
phase 3 topline order
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 risk phase 2/3 covid antiviral results
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study
Published: 2021-11-05 (Crawled : 11:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 8.64%
H: 0.0%
C: 0.0%
covid treatment phase 2 risk phase 2/3 antiviral
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Published: 2021-09-29 (Crawled : 12:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
positive results vaccine phase 3 topline order
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Published: 2021-08-30 (Crawled : 11:00) - biospace.com/
PFE A | $25.81 1.65% 15M
|
Health Technology
|
| O: -2.47%
H: 2.08%
C: 1.21%
positive results dermatitis phase 3 trial topline atopic dermatitis
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.